Evgen Pharma Share Discussion Threads

[njb67] 17/2/2021 11:34

EVG value the ARDS indication at circa £250m in total based on out licensing the asset, so this would give them significant funds to accelerate and fund the other indications.

Lets see what the interim results show, imv the odds are in favour of them needing to continue the study.

Long term hold.

[moneymunch] 17/2/2021 11:33

I see the first TR1 has arrived, and we should have a flurry in the couple of weeks or so with disclosure of who is holding the new placing shares, which will represent c50% of the enlarged capital , and await with interest who the new high quality investors are that Huw has already given a warm welcome...it's all very exciting imho.;-)

[moneymunch] 17/2/2021 11:29

Yes indeed njb, everything firmly crossed for the thumbs up from the DSMB and good news from Prof Chalmers on SFX-01 efficacy...this could sky rocket on such news. Gl :-)

[njb67] 17/2/2021 11:25

MM

If the interim look reveals exceptional efficacy results, then yes, very positive.

If the results are non-exceptional, then according to both the company and its broker, they would expect the study to run for another 12 months or so.

We will know in about a couple of months time which way this has landed.

[moneymunch] 17/2/2021 11:13

More likely, as I've suggested many times previously to much derision and gnashing of teeth, no doubt they want to check out interim data to make sure it's working as hoped, rather than waste valuable time and resources on a drug that doesn't work, especially in the urgency and priority in finding treatments that do work...positive news from the DSMB and Prof Chalmers will be a game changer.Gla :-)

[njb67] 17/2/2021 10:09

On Target

My inexpert view is that it could be due to the slow down in recruitment rates and the expectation that it could take another Covid season (winter 2021/2022) to fill the trial. So maybe worth having a look rather than waiting another 12 months for the results.

[on target] 17/2/2021 09:32

Any thoughts on why they might have chosen to do these 'extra' assessments, particularly the efficacy assessment by the sponsor? Are there any precedents for this?

[moneymunch] 17/2/2021 07:59

Thanks all, great news this morning and getting ready for a significant re-rate or two, especially 1st week of March with the placing done and dusted..Evgen has multiple shots on multiple targets, all of which could deliver Transformational upside...Evgen are all set for Go!!! :')

[riggerbeautz] 17/2/2021 07:50

Yep expect a lot of grinding come Spring.

Don’t think I’ll be churning anymore for awhile. Time to sit on hands.

[bocker01] 17/2/2021 07:49

Absolutely spot on MM! WELL DONE!

[bumpa33] 17/2/2021 07:47

Hopefully so Rb, it’s not too long to wait coupled with we also now have definitive timelines. And then there’s all the other potential news flow on other trials/indications, new stuff etc. I’d expect a slow grind higher from here. But hey, this is the mkt so who knows :)

[riggerbeautz] 17/2/2021 07:43

Reduced the wait now Bumpa, should help get rid of any cheap shares wanting out eh.

[amaretto1] 17/2/2021 07:34

I'm with u MM !!Been investing long enough to see the the traits of others !!!

[wanobi] 17/2/2021 07:34

great news, many thanx MM, Rb & Bumpa, cheers Wan :-)

[bumpa33] 17/2/2021 07:32

interesting that in addition to the DSMB review that Dundee Uni will be carrying out its own assessment...?

So from “early Q2” we should be getting data first on safety and then efficacy.